AKYA AKOYA BIOSCIENCES INC

Akoya to Participate at Four Upcoming Investor Conferences

Akoya to Participate at Four Upcoming Investor Conferences

MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences.

  • H.C. Wainwright 24th Annual Global Investment Conference (New York, NY)

    Presentation on Monday, September 12th at 11.30 AM ET

  • Morgan Stanley 20th Annual Global Healthcare Conference (New York, NY)

    Fireside chat on Wednesday, September 14th at 8:35 AM ET

  • Capital One Spatial Biology & Proteomics Summit (Virtual)

    Spatial Biology & Single Cell panel discussion on Wednesday, September 28th at 10:15 AM ET

    Executive panel discussion on Wednesday, September 28th at 1:00 PM ET
  • Bank of America Healthcare Innovation Forum (Virtual)

    Spatial Biology & Single Cell panel discussion on Thursday, September 29th at 11 AM ET

A live and archived webcast of the Morgan Stanley Global Healthcare Conference will be available on the “Investors” section of the Akoya website at .

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit .

Investor Contact:

Priyam Shah

Sr. Director, Investor Relations

Akoya Biosciences, Inc.

Media Contact:

Christine Quern

(617) 650-8497

 



EN
31/08/2022

Underlying

AKYAAKOYA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKOYA BIOSCIENCES INC

 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and Enable Medicine Launch the Largest Commercially ...

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas >8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the ...

April 24, 2025 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Bre...

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 ADC assay now available through ABS; customer study proves IO60 is a spatial workhorse MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the —Akoya’s flagship ultrahigh-plex immuno...

April 24, 2025 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC)...

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore’s public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapor...

April 23, 2025 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycle...

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, In...

April 2, 2025 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain opti...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch